The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study

Abstract

Population pharmacokinetics and simulation techniques currently play an important role in new drug development. This paper illustrates the potential value of those methods in postmarketing safety assessment, using buflomedil in elderly patients as an example. We retrospectively assessed the risk of buflomedil overdosing associated with the latest dosing recommendations of the French Drug Agency (AFSSAPS). First, buflomedil concentrations measured in 24 elderly patients were analysed with a nonparametric population approach. Then, the pharmacokinetic model was used to perform a 1000-patient Monte Carlo simulation for the two recommended buflomedil dosage regimens. The maximum concentrations calculated after 10 days of therapy were compared with levels observed in reported cases of toxicity to assess the probability of overdosing. A three-compartment model best fit concentration data. Population predictions showed little bias (-0.14 mg/L) and good precision (8.73 mg(2) /L(2)). Overall results of the simulation study showed that the application of the two recommended dosage regimens of buflomedil was associated with overdosing (C(max)> 10 mg/L) and potential toxicity in 2.9% of geriatric patients. In patients with mild renal impairment, who may receive the higher-dosage regimen by therapeutic error, the probability of overdosing was 6.2%. Despite specific dosing recommendations in case of renal impairment, this study shows that the use of buflomedil could be associated with significant risk of overdosing in geriatric patients. Such results might have enhanced decision-making when buflomedil safety was reassessed by AFSSAPS in 2006. The retrospective case of buflomedil illustrates how these methods may be valuable in postmarketing safety evaluation of potentially toxic drugs.

Solution‐driven approaches to generic substitution challenges – a survey among international experts

“…The pharmacokinetic study by Laurent Bourguignon et al. proved that even the application of current buflomedil (classified as NTI) dosing guidelines posed by the French medical agency (AFSSAPS) cannot totally prevent overdosing in patients . Other specific groups of problematic therapeutic equivalence include advanced release technology drugs, anticonvulsants, anti‐arrhythmics, psychotropic drugs, contraceptives, and alternative formulations (i.e., a different salt of the same active ingredient), or polymorphic drugs .…”

Nonparametric Methods in Population Pharmacokinetics

“…They are based on the random generation of a large number of PK parameter sets (classically 1000 to 10 000) representing virtual subjects. Simulations have various applications including model evaluation (with simulation‐based diagnostics such as VPCs and NPDEs 35 ), dosing simulations and dosage design, 36,37 probability of target attainment, and determination of minimum inhibitory concentration breakpoints for antimicrobials 38,39 and clinical trial simulations 40 …”

Covariate Pharmacokinetic Model Building in Oncology and its Potential Clinical Relevance

“…In cases were substantial shrinkage is present, a model building process involving more direct testing and less or no reliance on EBE-based diagnostics should be considered. Additionally, other types of diagnostics ought to be used in these cases, for example, simulation-based diagnostic (48) or conditional-weighted residuals (49).…”